Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350056 | 1.00 | OPRL1 (0.43) | OPRL1MAOBMAOACNR2NPY1R | |
| SCHEMBL6350052 | 1.00 | OPRL1 (0.43) | OPRL1MAOBMAOACNR2NPY1R | |
| SCHEMBL9577315 | 1.00 | OPRL1 (0.43) | OPRL1MAOBMAOACNR2NPY1R | |
| SCHEMBL9577309 | 1.00 | OPRL1 (0.43) | OPRL1MAOBMAOACNR2NPY1R | |
| SCHEMBL11365814 | 0.94 | OPRL1 (0.44) | OPRL1MAOBMAOA | |
| SCHEMBL11365818 | 0.94 | OPRL1 (0.44) | OPRL1MAOBMAOA | |
| SCHEMBL11365817 | 0.94 | OPRL1 (0.44) | OPRL1MAOBMAOA | |
| Hydrochloric Acid SCHEMBL7313828 | 0.93 | MAOB (0.46) | OPRL1MAOBMAOANPY1RHTT | |
| SCHEMBL6354142 | 0.90 | SLC6A2 (0.45) | MAOBSLC6A2SLC6A4 | |
| SCHEMBL6354146 | 0.90 | SLC6A2 (0.45) | MAOBSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1334087-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-0260121-B1 | INOSOSE DERIVATIVES, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
| EP-0240175-B1 | INOSOSE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-5004838-A | Inosose derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4898986-A | Inosose derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| US-4824943-A | Inosose derivatives and production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0137251-B1 | BISMORPHOLINES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-HYDROLYSIS AGENTS | BAYER AG (DE) | 1988-09-28 | — | — | EP | disclosed |
| EP-0260121-A2 | Inosose derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0240175-A1 | Inosose derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-10-07 | — | — | EP | disclosed |
| EP-0137251-A2 | Bismorpholines, process for their preparation and their use as anti-hydrolysis agents | BAYER AG (DE) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | GRIN2A, GRIN1, GRIK5 | OPRL1 57/4885MAOB 1368/4885MAOA 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.